Neoadjuvant zoledronic acid for HER2-positive breast cancer: the Zo-NAnTax trial

Background: Preclinical evidence suggests that zoledronic acid (ZOL) works synergistically with chemotherapy by enhancing anti-tumor activity. ZOL blocks the mevalonate pathway and may indirectly interact with human epidermal growth factor receptor 2 (HER2) pathway activation. The clinical efficacy...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Susanne Crocamo, Renata Binato, Bruno de Paula, Giselle Vignal, Lídia Magalhães, Roberta Sarmento, Maria Theresa Accioly, Isabele Small, Sandra Gioia, Pedro Maroun, Pamela Moutinho, Vivianne Freitas, Karuline Catein, Eliana Abdelhay
Format:	Artigo
Sprog:	Inglês
Udgivet:	SAGE Publishing 2019-05-01
Serier:	Therapeutic Advances in Medical Oncology
Online adgang:	https://doi.org/10.1177/1758835919853971
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!